Search Results

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.